UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS On

UNAUDITED PRO FORMA COMBINED FINANCIAL

HC Group Holdings I, LLC ("HC I") and HC Group Holdings II, Inc. ("HC II") entered into a definitive agreement

(the "Merger Agreement") to merge with and into a wholly-owned subsidiary of BioScrip, Inc. ("BioScrip"),

a national provider of infusion and home care management solutions, along with certain other subsidiaries of BioScrip and HC II.

The merger (the "Merger") contemplated by the Merger Agreement (the "Merger Agreement") was completed on

August 6, 2019. The Merger was accounted for as a reverse merger under the acquisition method of accounting for business combinations

with Option Care, Inc. ("Option Care") being considered the accounting acquirer and BioScrip being considered the legal

acquirer. Following the close of the transaction, BioScrip was rebranded as Option Care Health, Inc. (the "Company").

The following unaudited

pro forma combined statement of income of the Company presents the results of operation for the year ended December 31, 2019 assuming

the following occurred on January 1, 2019: (i) the consummation of the Merger, (ii) the financing of the senior credit facilities,

including a senior secured first lien term loan facility (the "First Lien Term Loan"), a first lien asset-based revolving

credit facility (the "ABL Facility") and a second lien secured notes facility (the "Second Lien Notes")

incurred in connection with the Merger and (iii) the issuance of new equity in connection with the Merger (collectively "Merger

forma combined statement of income for the year ended December 31, 2019 combines the historical consolidated statement of income

of the Company for the year ended December 31, 2019 and the historical consolidated statement of income of BioScrip for the period

January 1, 2019 to August 5, 2019. A pro forma balance sheet as of December 31, 2019 is not presented as the Merger is reflected

in the Company's consolidated balance sheet as of December 31, 2019. The historical consolidated financial information has

been adjusted in the unaudited pro forma combined statement of income to give effect to pro forma events that are (1) directly

attributable to the Merger, (2) factually supportable and (3) expected to have a continuing impact on the combined results.

forma combined statement of income was derived from and should be read in conjunction with the accompanying notes, as well as the

historical consolidated financial statements and the related notes of the Company contained in its Annual Report on Form 10-K for

the year ended December 31, 2019 and BioScrip's historical audited and interim unaudited consolidated financial statements.

forma combined financial information has been prepared by management and is for illustrative and informational purposes only. The

unaudited pro forma combined financial information is not necessarily indicative of what the combined company's results of

operations actually would have been had the Merger Transactions been consummated as of the date indicated. In addition, the unaudited

pro forma combined statement of income does not purport to project the future financial position or operating results of the combined

to finalize the purchase price allocation within the 12-month period following the acquisition date, during which certain contingent

liabilities acquired may be revised as appropriate. Accordingly, the pro forma adjustments are preliminary and being provided solely

for the purpose of providing pro forma financial statements and are subject to revision based on a final determination of fair

value as of the date of acquisition. Differences between these preliminary estimates and the final acquisition accounting may have

a material impact on the accompanying unaudited pro forma combined statement of income and the combined company's future results

of operations and financial position.

forma combined statement of income does not reflect any expected cost savings, operating synergies or revenue enhancements that

the combined company may achieve as a result of the Merger Transactions, any termination, restructuring or other costs to integrate

the operations of BioScrip or the costs necessary to achieve any such cost savings, operating synergies or revenue enhancements.

UNAUDITED PRO FORMA COMBINED STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2019

(in thousands except per share amounts)

See accompanying notes to the unaudited pro forma combined

financial information.

NOTES TO UNAUDITED PRO FORMA COMBINED STATEMENT OF INCOME

HC I and HC II entered into the Merger Agreement to merge with and into a wholly owned subsidiary of BioScrip along with certain

other subsidiaries of BioScrip and HC II. The Merger contemplated by the Merger Agreement was completed on August 6, 2019 (the

the Merger Agreement, shares of HC II common stock issued and outstanding immediately prior to the Merger Date were converted into

542,261,567 shares (135,565,392 equivalent shares after adjusting for the one share for four share reverse stock split) of

BioScrip common stock, par value $0.0001 (the "BioScrip common stock"). BioScrip also issued an additional

28,193,428 shares (7,048,357 equivalent shares after adjusting for the one share for four share reverse stock split) to HC

I in respect of certain outstanding unvested contingent restricted stock units of BioScrip, which are held in escrow to prevent

dilution related to potential additional vesting on certain share-based instruments. In conjunction with the Merger, holders of

BioScrip preferred shares and certain warrants received 3,458,412 additional shares (864,603 equivalent shares after adjusting

for the one share for four share reverse stock split) of BioScrip common stock and preferred shares were repurchased for $125.8

million of cash. In addition, all legacy BioScrip debt was settled for $575.0 million. As a result of the Merger, BioScrip's

stockholders hold approximately 19.2% of the combined company, and HC I holds approximately 80.8% of the combined

company. Following the close of the Merger Transactions, BioScrip was rebranded as Option Care Health, Inc. ("Option Care

Health", or the "Company"). The combined company's stock was listed on the Nasdaq Global Select Market

as of December 31, 2019.

liquidation preference paid to BioScrip preferred shareholders, as well as other fees and expenses related to the Merger Transactions,

primarily through debt financing, as described further in Note 4B Interest Expense, and cash on hand.

forma combined financial information was prepared using the acquisition method of accounting and was based on the historical financial

statements of Option Care and BioScrip. The unaudited pro forma combined statement of income for the year ended December 31, 2019

and adjustments are presented as if the Merger had occurred on January 1, 2019.

The acquisition method

of accounting is based on Accounting Standards Codification ("ASC") Topic 805, "Business Combinations"

("ASC 805"), and uses the fair value concepts as defined in ASC Topic 820, "Fair Value Measurement" ("ASC

820"). Fair value is defined in ASC 820 as the price that would be received to sell an asset or paid to transfer a liability

in an orderly transaction between market participants at the measurement date. Market participants are assumed to be buyers or

sellers in the most advantageous market for the asset or liability. Fair value measurement for an asset assumes the highest and

best use by these market participants. Fair value measurements can be highly subjective and it is possible the application of reasonable

judgment could develop different assumptions resulting in a range of alternative estimates using the same facts and circumstances.

forma combined financial information has been compiled in a manner consistent with the accounting policies of Option Care Health

and includes certain reclassifications to conform BioScrip's historical statement of income to the Company's accounting

policies and classifications.

The following provides

explanations of the various adjustments to the unaudited pro forma combined statement of income:

Incremental depreciation

and amortization of $6.7 million for the period January 1, 2019 to August 5, 2019 was recorded in operating costs and expenses

related to the fair value adjustments of acquired property and equipment and intangible assets. Additionally, incremental medical

equipment depreciation expense of $0.7 million for the period January 1, 2019 to August 5, 2019 was recorded in cost of revenue

related to the fair value adjustments of acquired medical equipment.

Represents an increase

to interest expense of $0.4 million for the twelve months ended December 31, 2019, which includes the following (in thousands):

A 1/8 percent variance in interest

rates would result in a $1.7 million change to pro forma interest expense for the twelve months ended December 31, 2019.

Represents the removal

of $62.7 million for the twelve months ended December 31, 2019, incurred by the combined companies in conjunction with this Merger

for transaction related fees and expenses that will not recur on an ongoing basis. Also represents the removal of Management Service

Agreement fees related to a prior acquisition of $1.5 million for the period January 1, 2019 to August 5, 2019, as these fees discontinued

upon completion of the Merger.

Represents the removal

of this income as the BioScrip stock warrants are no longer treated as liability-based instruments after the Merger.

Represents the removal

of expenses related to the extinguishment of debt retired by the Company in conjunction with the Merger of $6.8 million. Of these

expenses, $5.5 million related to debt issuance costs and deferred financing fees incurred with the issuance of the First Lien

Term Loan, which were written off upon extinguishment. The remaining $1.3 million was comprised of financing fees paid to third

parties attributed to the insubstantial modification of Option Care's previous first lien term loan and previous second lien

term loan, which were expensed as incurred.

Represents the estimated